## 1 Metformin associates with improved myocardial perfusion reserve and

# 2 <u>survival in patients with Type 2 Diabetes Mellitus</u>

3 4

5

#### Brief title: Metformin associates with improved survival in T2DM

6	Noor Sharrack MBChB <sup>1</sup> , Kristopher D Knott PhD <sup>2, 3</sup> , Gaurav S Gulsin PhD <sup>4</sup> , Tushar Kotecha			
7	PhD <sup>3,5</sup> , Louise AE Brown PhD <sup>1</sup> , Jian L Yeo MBChB <sup>4</sup> , Aldostefano Porcari MD <sup>5,6</sup> , Robert D			
8	Adam MD <sup>2,3,7</sup> , Sharmaine Thirunavukarasu MBChB <sup>1</sup> , Amrit Chowdhary MBBS <sup>1</sup> , Eylem			
9	Levelt MBBS DPhil <sup>1</sup> , James C Moon MD <sup>2,3</sup> , Gerry P McCann MD <sup>4</sup> , Marianna Fontana			
10	PhD <sup>3,5</sup>	, Peter Kellman PhD <sup>8</sup> , Theresa Munyombwe PhD <sup>1,9</sup> , Christopher Gale PhD <sup>9,10,11</sup> ,		
11	David	L Buckley PhD <sup>1</sup> , John P Greenwood PhD <sup>1</sup> , Peter P Swoboda PhD <sup>1</sup> , Sven Plein PhD <sup>1</sup>		
12				
13	Institu	itions		
14				
15	1.	Biomedical Imaging Science Department, Leeds Institute of Cardiovascular and Metabolic		
16		Medicine, University of Leeds, Leeds, United Kingdom		
17	2.	Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom		
18	3.	University College London (UCL) Institute of Cardiovascular Science, London, United		
19		Kingdom		
20	4.	Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester		
21		Cardiovascular Biomedical Research Centre, Glenfield Hospital, University Hospitals of		
22		Leicester NHS Trust, Leicester, United Kingdom		
23	5.	National Amyloidosis Centre, Division of Medicine, Royal Free Campus, University College		
24		London, London, United Kingdom		
25	6.	Centre for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department,		
26		Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste,		
27		Italy		
28	7.	Carol Davila University of Medicine and Pharmacy, Bucharest, Romania		
29	8.	National Heart, Lung, and Blood Institute, National Institutes of Health, Department of		
30		Health and Human Services, Bethesda, Maryland, United States of America		
31	9.	Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds,		
32		United Kingdom		
33	10.	Leeds Institute for Data Analytics, University of Leeds, Leeds, United Kingdom		
34	11.	Department of Cardiology, Leeds Teaching Hosptislas NHS Trust, Leeds, UK		
35				

36 Address for Correspondence:

37	
38	Professor Sven Plein
39	Leeds Institute of Cardiovascular and Metabolic Medicine
40	University of Leeds
41	Leeds
42	LS2 9JT
43	United Kingdom
44	Tel +44 113 39 22650
45	Email: s.plein@leeds.ac.uk
46	
47	Twitter handle: @Sven_plein
48	
49	A multicentre study from the United Kingdom shows that in patients with Type 2 Diabetes Mellitus,
50	metformin associates with improved myocardial perfusion reserve (MPR) and survival.
51 52	
52 53	Word count 3117
54	

#### 55 Abstract

#### 56

#### 57 Background

58 Metformin is an antihyperglycemic agent frequently used in the treatment of Type 2 Diabetes 59 Mellitus (T2DM). Patients with T2DM are at increased risk of cardiovascular diseases, 60 including coronary artery disease (CAD), silent myocardial infarction (MI) and coronary 61 microvascular dysfunction (CMD), all of which can be detected and quantified using 62 Cardiovascular Magnetic Resonance (CMR). We explored the association between 63 metformin use, stress Myocardial Blood Flow (MBF), Myocardial Perfusion Reserve (MPR), 64 survival and major adverse cardiovascular and cerbrovasular events (MACCE; a composite 65 of all-cause death, MI, stroke, heart failure hospitalisation and coronary revascularisation) in 66 patients with T2DM.

67

#### 68 Methods

A multi-centre study of patients with T2DM, and a cohort of healthy controls underwent quantitative myocardial perfusion CMR. Global MBF and MPR were derived using an automatic artificial intelligence-supported process. Multivariable regression analysis and cox proportional hazard models quantified associations between metformin use, MBF, MPR, allcause death and MACCE.

74

#### 75 Results

76 Analysis included 572 patients with T2DM (68% prescribed metformin) with median follow-77 up 851 days (interquartile range 935-765). Metformin use was associated with an increase in 78 MPR of 0.12 [0.08-0.40], P=0.004. There was a total of 82 (14.3%) first MACCE in all 79 T2DM patients including a total of 25 (4.4%) deaths. Although the number of first MACCE 80 events was similar for patients prescribed metformin (53 (14%)) compared to those who were 81 not (29 (15.8%) (P=0.73)), there was a total of 9 deaths (2.3%) in patients prescribed 82 metformin compred to 16 (8.7%) in patients who were not, adjusted hazard ratio 0.29 [95% 83 CI 0.12-0.73] P=0.009).

84

#### 85 Conclusion

86 In patients with T2DM, metformin use is associated with higher MPR and improved survival.

#### 88 **Clinical Perspective**

89

90 Patients with Type 2 Diabetes Mellitus (T2DM) are at increased risk of cardiovascular 91 disease. Cardiovascular Magnetic Resonane (CMR) can be used to detect and quantify 92 absolute stress myocardial blood flow (MBF) and myocardial perfusion reserve (MPR), both 93 of which are objective measures of coronary microvascular function. Metformin is frequently 94 used in the treatment of T2DM. We investigated the association between metformin use, 95 CMR-derived stress MBF, MPR and clinical outcomes in patients with T2DM.

96

97 In a longitudinal cohort study of patients with T2DM, metformin use was associated with

- 98 higher MPR as a marker of microvascular function, and improved survival after adjusting for
- 99 certain confounding parameters.
- 100

101 Further prospective studies are needed to confirm the association between metformin use and

102 improved MPR and reduced mortality, as well as to clarify the mechanisms responsible and

103 quantify the dose these associated outcomes are observed.

104

#### 105 **Central illustration**



108 Key words: Type 2 Diabetes Mellitus (T2DM), Myocardial Perfusion Reserve (MPR), stress

109 Myocardial Blood Flow (MBF), metformin, endothelial function, major adverse

- 110 cardiovascular and cerbrovasular events (MACCE).
- 111

### 112 Abbreviations

113

114	CAD	Coronary Artery Disease
115	CMD	Coronary Microvascular Dysfunction
116	CMR	Cardiovascular Magnetic Resonance
117	T2DM	Type 2 Diabetes Mellitus
118	LV	Left Ventricle
119	LVEF	Left Ventricular Ejection Fraction
120	MI	Myocardial Infarction
121	MACCE	Major Adverse Cardiovascular and Cerebrovascular Events
122	MBF	Myocardial Blood Flow
123	MPR	Myocardial Perfusion Reserve
124		
125		
126		
127		
128		
129		
130		
131		
132		
133		
134		
135		

136

- 138
- 139
- 140
- 141

#### 142 Introduction

143

144 Cardiovascular disease is the commonest cause of death in patients with Type 2 Diabetes
145 Mellitus (T2DM)<sup>1</sup>. T2DM is associated with an increased risk of epicardial coronary artery
146 disease (CAD), silent myocardial infarction (MI) and coronary microvascular dysfunction
147 (CMD)<sup>2-4</sup>.

148

Metformin is the most widely used antihyperglycemic agent worldwide and is first-line in most recommendations for the treatment of patients with T2DM<sup>5-8</sup>. As well as its glucose lowering and weight loss benefits), it was also shown to be associated with a 39% lower risk of myocardial infarction compared to conventional therapy in the United Kingdom Prospective Diabetes (UKPDS) Study<sup>9</sup>. In a more recent study, metformin use was associated with a nearly 40% reduction in cardiovascular mortality when compared to sulfonylurea monotherapy<sup>10</sup>.

156

157 Metformin may improve endothelial function as well as reducing insulin resistance in patients with T2DM<sup>11, 12</sup>. In non-diabetic women with chest pain and angiographically normal 158 159 coronary arteries, metformin was shown to improve coronary microvascular function and 160 decrease MI incidence<sup>13</sup>. In the retrospective Prevention of REStenosis with Tranilast and its 161 Outcomes (PRESTO) trial, the use of metformin in diabetic patients undergoing coronary intervention decreased the risk of death and MI (relative risk reduction of 79%) compared to 162 patients treated with a sulforylurea or insulin<sup>14</sup>. Nevertheless, the mechanism of benefit of 163 164 metformin is not clear and warrants further investigation, since meta-analyses of intensive 165 versus normal glucose control have shown minimal benefit on cardiovascular outcomes<sup>15</sup>.

166

167 CMR allows simultaneous assessment of cardiac function, detection of MI, regional 168 ischaemia suggesting epicardial CAD and, with quantitative perfusion analysis, absolute 169 measures of myocardial blood flow (MBF) for the assessment of coronary microvascular 170 dysfunction. Previous studies have shown that patients with T2DM have reduced global 171 myocardial perfusion reserve (MPR) and stress MBF, independent of significant flow limiting epicardial CAD, suggestive of CMD<sup>16, 17</sup>. We aimed to test the hypothesis that 172 173 metformin use in patients with T2DM is associated with improved stress MBF and MPR and 174 is associated with improved survival and reduced major adverse cardiovascular and

175 cerbrovasular events (MACCE; a composite of all-cause mortality, MI, stroke, heart failure

- 176 hospitalisation and coronary revascularisation).
- 177

178 Methods

179

#### 180 Participants

181

182 Patients aged 18 years or older, with a diagnosis of T2DM, undergoing quantitative stress 183 perfusion CMR, were recruited from four United Kingdom centres (St Bartholomew's 184 Hospital, Barts Heart Centre, London; Glenfield Hospital, University Hospitals of Leicester 185 NHS Trust, Leicester; Leeds Teaching Hospitals NHS Foundation Trust, Leeds and the Royal 186 Free Hospital, Royal Free London NHS Foundation Trust, London) between September 187 2016 and May 2021. Diagnosis of T2DM was based on a HbA1c >48mmol/l or a known 188 diagnosis of T2DM. Exclusion criteria included contraindications to adenosine, gadolinium-189 based contrast or MRI.

190

All participants had received quantitative myocardial perfusion stress CMR for clinical or
research indications. Those with sub-optimal image quality, mistriggering or other artefacts
were excluded.

194

195 Controls

196

We recruited 52 age- and sex-matched, healthy controls with no past medical history of cardiac disease or major risk factors from two cardiac centres (Leeds Teaching Hospitals and Glenfield Hospital) between September 2016 and May 2021. Exclusion criteria included a known past medical history of hypertension, hypercholesterolaemia, diabetes mellitus (DM), smoking, previous CAD or revascularisation or perfusion defect on stress CMR, contraindications to adenosine, gadolinium-based contrast or MRI and subsequent evidence of abnormal late gadolinium enhancement (LGE) on CMR.

204

205

206 Clinical Outcomes

Patient co-morbidities and clinical outcomes were collated from electronic patient records and the National Health Service (NHS) Spine Portal through deterministic linkage using each patient's unique NHS identification number. Co-morbidities recorded included hypertension, dyslipidaemia, atrial fibrillation, CAD, coronary revascularisation (percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery, MI, stroke or transient ischaemic attack (TIA) and cancer. All patients had provided written, informed consent and had more than one year of follow-up data available.

215

The joint primary outcomes were all-cause mortality and MACCE (a composite of all-cause mortality, MI, stroke, heart failure hospitalisation and coronary revascularisation). Where patients had more than one MACCE, the first event was used for analysis.

- 219
- 220

#### 221 Cardiovascular Magnetic Resonance imaging

222

223 CMR scans were performed on 1.5T (Magnetom Aera, Siemens Healthcare, Erlangen, 224 Germany) or 3T (Prisma, Siemens Healthcare, Erlangen, Germany) scanners with a standard 225 protocol consisting of localisers, short-axis and long-axis cine imaging, perfusion imaging 226 and late gadolinium enhancement (LGE) imaging. 169 (30%) patients were scanned on 1.5T 227 and 403 (70%) patients were scanned on 3T. All healthy controls were scanned on 3T. 228 Perfusion imaging on 1.5T scanners used a steady state free precession (SSFP) pulse 229 sequence and on 3T scanners a fast single-shot gradient echo (FLASH) pulse sequence. All 230 participants were instructed to abstain from caffeine for 24 hours before the study. For 231 perfusion imaging, adenosine was infused for a minimum of 3 minutes, at a rate of 140 232 micrograms/kg/min and increased up to a maximum of 210 micrograms/kg/min if there was 233 insufficient haemodynamic response (heart rate increase less than 10bpm) or there was no 234 symptomatic response, in line with standard clinical practice guidelines<sup>18</sup>. Images were 235 acquired during free breathing over at least 60 dynamics to allow for any patients with poor 236 ventricular function and consequent slow contrast uptake. A minimum interval duration of 237 ten minutes was kept between stress and subsequent rest perfusion acquisitions. Participants' 238 blood pressures and heart rates were recorded at regular intervals during adenosine infusion. 239 For each perfusion acquisition, an intravenous bolus of (0.05-0.75mmol/kg) gadobutrol 240 (Gadovist, Leverkusen, Germany) or gadoterate meglumine (Dotarem, Guerbet, Paris, 241 France) was administered at 4-5ml/s. Perfusion mapping was performed in three short axis

sections, using a dual sequence technique combining a low-resolution arterial input function
acquisition and a higher resolution myocardial perfusion acquisition as previously described
by Kellman et. al<sup>19</sup>.

245

#### 246 Image Analysis

247

248 Image analysis was undertaken by experienced operators at the site core lab. Those with poor 249 image quality were excluded. Measurement of cardiac volume parameters and the presence of 250 LGE were made using cvi42 software (Circle Cardiovascular Imaging, Calgary, Canada). 251 Left ventricular systolic and diastolic volume, ejection fraction, and the presence and 252 distribution (ischaemic or non-ischaemic) of LGE were recorded. Non-ischaemic LGE refers 253 to late gadolinium enhancement in a mid-myocardial or subepicardial pattern, as opposed to 254 ischaemic LGE, which is subendocardial. Rest and stress perfusion maps were generated 255 inline by an automatic artificial intelligence-supported process whereby myocardial blood 256 flow is quantified for each pixel of the myocardium in ml/g/min. By averaging all pixel 257 values in the 3 slices, global MBF and global MPR (ratio of stress to rest MBF) were derived<sup>19</sup>. Automatically derived perfusion maps were reviewed by experienced observers to 258 259 exclude data affected by gating and motion correction artefact and partial voluming affects.

260

#### 261 Statistical Analysis

262

263 Statistical analysis was performed using SPSS (IBM SPSS Statistics, version 27.0). 264 Normality was assessed through the Shaprio-Wilk test and variance was assessed by the 265 Leven's test for equality of variance. Continuous variables are presented as mean±SD. 266 Categorical variables are presented as absolute values and percentages. Means were 267 compared using the appropriate test, student t test for continuous variables and chi-squared  $(\chi^2)$  test for categorical variables. A P value of <0.05 was considered statistically significant. 268 269 Multivariable linear regression analysis, adjusting for age, sex, left ventricular ejection 270 fraction (LVEF), left ventricular mass (LV mass), left ventricular end diastolic volume 271 (LVEDV), hypertension, evidence of previous PCI, CABG surgery, MI, body surface area 272 (BSA) and ethnicity was undertaken to seek association between metformin, stress MBF and 273 MPR. Cox proportional hazard models adjusting for comorbidities and CMR parameters 274 sought associations between stress MBF and MPR with all-cause mortality and MACCE. For 275 the all-cause mortality model, we adjusted for age and LVEF (only two predictors using the

276 10 events per parameter rule of thumb) and for the MACCE model we adjusted for 8 277 parameters including age, LVEF, sex, LVEDV, LV mass, stress MBF, MPR and 278 hypertension. Kaplan-Meier curves represented hazard curves. Patient data was categorised 279 depending on whether the patient was prescribed metformin at the time of the CMR scan. 280 281 Results 282 283 Patient group 284 A total of 572 patients with T2DM were included with a median follow-up of 851 days (IQR 285 286 935-765) days. 287 288 **Patient characteristics** 289 290 Patient characteristics are shown in table 1 and are presented according to whether subjects 291 were prescribed metformin at the time of their CMR. Their mean age was 65± 10 years and 292 their mean HbA1c was  $59\pm 16$  mmol/mol. 25% of all patients (n=142) had known CAD with 293 previous MI, PCI or CABG surgery. 68% of all patients (n=388) were prescribed metformin. 294 Metformin positive and Metformin negative groups were well-matched for age and sex. 295 Patients prescribed metformin were more likely to have had previous PCI, MI or CABG 296 surgery (28% vs 19%, P=0.027) compared to those not prescribed metformin. They were 297 also more likely to be of Asian ethnicity (32% vs 22%, p=0.01), suffer from 298 hypercholesterolaemia (62% vs 54%, P=0.044) and have peripheral vascular disease (10% vs 299 4%, P=0.016). Patients who were prescribed metformin had higher mean HbA1c levels than 300 those not prescribed metformin ( $60\pm16$  mmol/mol vs  $56\pm15$  mmol/mol, respectively, 301 P=0.022). However, patients not prescribed metformin had a higher prevelance of atrial 302 fibrillation (21% vs 10%, P<0.001), previous stroke or transient ischaemic attack (10% vs 303 4%, P=0.008) and history of current smoking (25% vs 22%, p<0.001) compared to the non-304 metformin cohort. 305

Patients prescribed metformin were more likely to be on antiplatelet medication, statins,
gliclazide, sodium glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1

308 (GLP-1) agonists and calcium channel blockers (CCBs) (table 2). However, patients not

309 prescribed metformin, were more likely to be on mineralocorticoid receptor antagonists 310 (MRAs), diuretics or anticoagulants. 311 312 Healthy control group 313 314 Subjects in the healthy control group were not taking any medication. The mean age was 315  $64\pm 6$  years and 65% of them were of male sex. 316 317 **CMR** analysis 318 319 Patient group 320 321 169 (29.5%) of patients were scanned on 1.5T scanners and 403 (70.5%) were scanned on 3T 322 scanners. The mean ejection fraction of diabetic patients was  $57\pm15\%$  (table 3). 164 (29%) 323 had evidence of ischaemic scar on LGE indicating previous MI (table 3). Mean global stress 324 MBF in all patients was  $1.70 \pm 0.6$  ml/g/min and mean MPR was  $2.20 \pm 0.90$  (table 3). 325 326 Patients precribed metformin had significantly higher ejection fractions ( $59\pm14\%$  vs  $53\pm18\%$ , 327 P<0.001), stress MBF (1.74±0.6 ml/g/min vs 1.62±0.5 ml/g/min, P=0.019), MPR (2.29±0.9 328 vs 1.96±0.9, P<0.001) as well as significantly lower EDV and LV mass. There was no 329 significant difference in the degree of scar burden between the two groups. 330 331 Healthy control group 332 333 All healthy volunteers were scanned on 3T scanners. The average stress MBF of the healthy 334 control group was  $2.05 \pm 0.4$  ml/g/min and average MPR was  $3.40 \pm 0.7$ . 335 336 Multivariable regression analysis 337 338 Multivariable linear regression was carried out to ascertain the extent to which metformin use 339 is associated with stress MBF and MPR. The model was adjusted for factors known to be 340 associated with differences in stress MBF and MPR including age, sex, LVEF, LV mass, 341 LVEDV, hypertension, evidence of previous PCI, CABG surgery, MI, body surface area 342 (BSA) and ethnicity as well as for medications including CCBs, nitrates, SGLT-2 inhibitors,

343	GLP-1 agonists and gliclazide. Adjusted stress MBF and MPR values are reported in table 3.
344	For stress MBF, the regression coefficient for metformin had a value of 0.05 ([0.04-0.17],
345	P=0.21). This suggests that metformin use was associated with an increase of stress MBF by
346	0.05ml/g/min, although this did not meet statistical significance. For MPR, the regression
347	coefficient for metformin had a value of 0.12 ([0.08-0.40], P=0.004). This suggests that the
348	use of metformin is associated with an increase in MPR of 0.12, with statistical significance.
349	
350	Clinical outcomes
351	
352	There were 82 first MACCE (14.3%) including a total of 27 (4.7%) deaths, 15 (2.6%) MIs,
353	18 (3.1%) strokes, 20 (3.5%) heart failure hospitalisations and 43 (7.5%) episodes of
354	coronary revascularisation.
355	
356	Table 4 shows first MACCE events by metformin status. Although there was no significant
357	difference in first MACCE rates between the two groups, there was a significant reduction in
358	number of deaths in the metformin group (9 (2.3%) vs 16 (8.7%), P<0.001). There was also
359	a significantly lower incidence of stroke in the metformin group (8 (2.1%) vs 10 (5.4%),
360	P=0.031).
361	
362	Metformin was significantly associated with a reduction in all-cause mortality (figure 1).
363	After adjusting for age and LVEF, the adjusted hazard ratio for all-cause mortality was 0.29
364	([0.12-0.73], P=0.009 (table 5)). However, metformin use was not associated with reduced
365	first MACCE rate after adjusting for age, LVEF, sex, LVEDV, LV mass, stress MBF, MPR
366	and hypertension with an adjusted HR of 0.92 ([0.56-1.50], P=0.73) (table 5).
367	
368	
369	Discussion
370	
371	We sought to test the hypothesis that metformin use in patients with T2DM is associated with
372	improved coronary microvascular function, improved survival and a reduction in MACCE.
373	
374	The key findings in this study are that metformin use is associated with (1) improved MPR as
375	a marker of CMD and (2) an improvement in all-cause mortality after adjusting for important
376	parameters.

#### 377

#### 378 Association between metformin and MPR

379

380 To the authors knowledge, this is the first clinical study that has demonstrated an association 381 between metformin use and improved coronary microvascular function in patients with 382 T2DM. Obesity, insulin resistance, and endothelial dysfunction closely co-exist throughout the natural history of T2DM<sup>20</sup>. Endothelial dysfunction is considered an important event in 383 384 the development of microvascular complications in diabetes and is well recognised in patients 385 Insulin resistance itself may be central to the pathogenesis of endothelial with T2DM. 386 dysfunction. Patients with T2DM have been shown to have reduced MPR as manifestations of CMD caused by endothelial dysfunction<sup>16, 17</sup>. Metformin has been shown to improve 387 endothelial function<sup>21</sup>. A previous study conducted in 16 asymptomatic patients recently 388 389 diagnosed with T2DM using Positron Emission Tomography (PET), looked at the effect of 390 metformin treatment alone or with a combination of glimepiride/metformin on coronary endothelial function<sup>22</sup>. It showed that at baseline, the response of T2DM patients to cold 391 392 pressor test was reduced compared to controls, demonstrating endothelial dysfunction. 393 Following treatment with a combination of metformin/glimepiride, myocardial flow reserve 394 (MFR) and response to cold pressor testing MBF (% delta MBF) improved. Another study 395 conducted in patients with T2DM showed an improvement in endothelium-dependent 396 vasodilatation after administering metformin, assessed through forearm plethysmography. This change was also accompanied by a reduction of insulin resistance<sup>11</sup>. A study in rats who 397 were fed a high fat diet showed an improvement in MPR after administering a 4-week 398 treatment of metformin<sup>23</sup>. This study also showed that metformin treatment led to a robust 399 400 adenosine-induced increase in myocardial perfusion (+81%). The authors postulated that 401 metformin improved cardiac perfusion by restoring balance between vasoconstrictor and 402 vasodilator effects of modest insulin resistance. We postulate that an improvement in 403 endothelial function through the use of metformin in patients with T2DM, improves MPR. 404 We speculate that this effect was not seen with stress MBF on multivariable regression analysis since MPR is a better measure of endothelial dysfunction $^{24}$ . 405

406

#### 407 Metformin and improved survival

408

409 Our data confirm previous reports that metformin is associated with improved overall 410 survival. Despite having worse cardiovascular profiles, patients on metformin had higher

411 ejection fractions compared to patients not prescribed metformin. We speculate that this may 412 be secondary to more intense risk factor modification and drug treatment effects, for example 413 with SGLT-2 inhibitors and GLP-1 agonists, although we cannot establish the cause from this 414 study alone. The United Kingdom Prospective Diabetes Study (UKPDS) showed that 415 metformin use reduced diabetes-related mortality by 42% (P=0.017), all-cause mortality by 416 36% (P=0.011), MI by 39% (P=0.01) and any diabetes related endpoint by 32% (P=0.002)<sup>9</sup>. 417 In a recent systematic review, looking at 40 studies, metformin was shown to reduce 418 cardiovascular mortality, all-cause mortality and cardiovascular events in CAD patients<sup>25</sup>. 419 However, for MI and CAD patients without T2DM, metformin had no effect of reducing the 420 incidence of cardiovascular events. In our study, metformin was not associated with an 421 improvement in first MACCE rate. This is not surprising since patients prescribed metformin 422 had higher cardiovascular risk compared to patients not prescribed metformin. In patients 423 prescribed metformin there was also an increased prevalence of peripheral vascular disease 424 and hypercholesterolaemia. The association between metformin use and improved survival is 425 unclear; further research needs to be undertaken in this field. Recently, additional benefits of metformin have been reported including potential effects on cancer<sup>26, 27</sup>, cardiovascular 426 disease<sup>13</sup>, liver disease<sup>28</sup>, obesity<sup>29</sup>, neurodegenerative disease<sup>30</sup> and renal disease<sup>31</sup>. 427

428

#### 429 Improving mitochondrial function

430

T2DM is a metabolic disorder characterised by mitochondrial dysfunction and oxidative stress<sup>32</sup>. By increasing nitric oxide (NO) bioavailability, limiting interstitial fibrosis, reducing the deposition of advanced glycation end products (AGEs), and inhibiting myocardial cell apoptosis, metformin has been shown to reduce cardiac remodelling and hypertrophy, thereby preserving left ventricular systolic and diastolic function<sup>33, 34</sup>. Although we did not directly measure mitochondrial function in our study, these mechanisms may explain why patients taking metformin had higher ejection fractions, lower LVEDV and LV mass.

438

#### 439 Limitations

440

441 Several limitations should be acknowledged in this study. First, the study carries all the 442 inherent limitations of an observational study and since subjects were non-randomised, the 443 associations between metformin and improved survival and MPR found cannot imply 444 causation and may be secondary to one or more confounders. One should also consider the

445 potential for bias in the estimated coefficients due to the relatively small number of events 446 and large number of co-variates. There is also the possibility that sicker patients may not have 447 been prescribed metformin, leading to selection bias although this is unlikely to be the case in 448 our cohort, since the patients prescribed metformin had more cardiovascular morbidity 449 (increased prevalence of MI, PCI and CABG surgery, peripheral vascular disease and 450 hypercholesterolaemia). It may also be plausible that patients prescribed metformin were 451 better managed for conventional cardiovascular risk factors, due to the fact these patients tend 452 to be higher risk patients. Furthermore, since events were documented using electronic 453 patients records from different hospitals, there is a chance that events may have been missed. 454 Patients on metformin in the current study were more likely to be on other medications such 455 as gliclazides, nitrates, SGLT-2 inhibitors, GLP-1 agonists, and CCBs. Therefore, the 456 improvement in MPR observed may have been mediated by one or more combination drug 457 effects although we have adjusted for these in our multivariable linear regression analysis 458 models and there is no evidence in the literature that these medications affect MPR. 459 Furthermore, information on the duration of diabetes and the length of treatment with 460 metformin was not collected in all patients. Despite these limitations, this is an indication 461 that further research in this area, preferably in the form of a double blind, randomised 462 prospective placebo-controlled clinical trial, would be able to address some of the points 463 above.

464

465

#### 466 Conclusion

467

468 In patients with T2DM, we show that metformin use was associated with higher MPR, as a 469 marker of microvascular function, and is associated with improved overall survival.

# 470471 Acknowledgements

472

The authors thank the clinical staff of the CMR department, and the National Institute ofHealth Research nurses based at Leeds General Infirmary.

475

476 Funding

477

478 This study was supported directly and indirectly from the National Institute for 479 Health Research Biomedical Research Centres at University College London Hospitals and 480 Barts Health National Health Service Trusts. Recruitment in Leicester was funded through 481 BHF Clinical Research Training Fellowship (G. Gulsin; FS/16/47/32190) and a NIHR 482 Research Professorship (G. McCann; RP-2017-08-ST2-007). Leeds studies were funded by 483 British Heart Foundation with ethical approval from 17/YH/0300, 18/YH/0168 and 484 18/YH/01900. This research is supported by the National Institute for Health Research 485 (NIHR), through the Local Clinical Research Networks and the NIHR Leeds and Leiciester 486 Clinical Research Facilities. SP is supported by a British Heart Foundation Chair 487 (CH/16/2/32089). EL acknowledges support from the Welcome Trust (221690/Z/20/Z). 488 RDA received funding from the Romanian Society of Cardiology (Research Grant No. 489 95/01.09.2020).

490

#### 491 Disclosures

492

493 The authors declare that they have no competing interests. There are no disclosures with494 industry.

495

#### 496 Author contributions

497

498 Study concepts/study design or data acquisition or data analysis/interpretation NS, KK, GSG, 499 TK, LAEB, JLY, AP, RDA, ST, AC, EL, JM, GPM, MF, PK, JPG, PPS, SP; manuscript 500 drafting or manuscript revision for important intellectual content: NS, SP, PPS, 501 JPG,GPM,CG; approval of final version of submitted manuscript, all authors; agrees to 502 ensure any questions related to the work are appropriately resolved, all authors; statistical 503 analysis: NS, GSG, SP,TM,CG; and manuscript editing: NS,SP,JPG,GPM,CG.

#### 504

#### 505 Ethics approval and consent to participate

506

507 All the patients provided written informed consent for their inclusion and approval was 508 provided by the respective local ethics committees from each site and conducted in 509 accordance with the Declaration of Helsinki.

510 Leeds data was obtained with ethical approval obtained by Leeds Research Ethics Committee 511 (REC), Leeds, United Kingdom, reference 17/YH/0300, 18/YH/0168 and 18/YH/01900. 512 Barts data used ethical approval from East of England, Cambridge Central Research Ethics 513 Committee, United Kingdom, REC 14/EE/0007. Royal Free data was provided by the 514 University College London/University College London Hospital Joint Committees on the 515 Ethics of Human Research for recruitment at Royal Free Hospital (REC reference 516 07/H0715/101), United Kingdom. Leicester data ethical approval was provided by the UK 517 Health Research Authority Research Ethics Committee (reference 17/WM/0192).

518 Consent for publication

519

- 520 Consent for publication was obtained from all authors.
- 521

### 522 Availability of data and materials

523

524 The datasets used and analysed during the current study are available from the corresponding

- 525 author on reasonable request.
- 526

#### 527 **<u>References</u>**

528

Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, Di Palo KE,
 Golden SH, Sperling LS, American Heart Association Diabetes Committee of the Council on
 L, Cardiometabolic H, Council on Arteriosclerosis T, Vascular B, Council on Clinical C and
 Council on H. Comprehensive Management of Cardiovascular Risk Factors for Adults With
 Type 2 Diabetes: A Scientific Statement From the American Heart Association. *Circulation*.
 2022;145:e722-e759.

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M,
Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Juni P, Lettino M, Marx N,
Mellbin LG, Ostgren CJ, Rocca B, Roffi M, Sattar N, Seferovic PM, Sousa-Uva M, Valensi
P, Wheeler DC and Group ESCSD. 2019 ESC Guidelines on diabetes, pre-diabetes, and
cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J*.
2020;41:255-323.

541 3. Kannel WB and McGee DL. Diabetes and glucose tolerance as risk factors for 542 cardiovascular disease: the Framingham study. *Diabetes Care*. 1979;2:120-6.

543 4. Stamler J, Vaccaro O, Neaton JD and Wentworth D. Diabetes, other risk factors, and
544 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention
545 Trial. *Diabetes Care*. 1993;16:434-44.

546 5. Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, D'Alessio DA 547 and Davies MJ. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A 548 Consensus Report by the American Diabetes Association (ADA) and the European 549 Association for the Study of Diabetes (EASD). *Diabetes Care*. 2020;43:487-493.

550 6. *Type 2 diabetes in adults: management* London; 2015.

551 7. International Diabetes Federation Guideline Development G. Global guideline for 552 type 2 diabetes. *Diabetes Res Clin Pract*. 2014;104:1-52.

8. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA,
Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger
G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD and
Umpierrez GE. Consensus Statement by the American Association of Clinical
Endocrinologists and American College of Endocrinology on the Comprehensive Type 2
Diabetes Management Algorithm - 2017 Executive Summary. *Endocr Pract.* 2017;23:207238.

560 9. Effect of intensive blood-glucose control with metformin on complications in
561 overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study
562 (UKPDS) Group. *Lancet*. 1998;352:854-65.

Johnson JA, Majumdar SR, Simpson SH and Toth EL. Decreased mortality associated
with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. *Diabetes Care*. 2002;25:2244-8.

11. Mather KJ, Verma S and Anderson TJ. Improved endothelial function with metformin
in type 2 diabetes mellitus. *J Am Coll Cardiol*. 2001;37:1344-50.

Vitale C, Mercuro G, Cornoldi A, Fini M, Volterrani M and Rosano GM. Metformin
improves endothelial function in patients with metabolic syndrome. *J Intern Med.*2005;258:250-6.

571 13. Jadhav S, Ferrell W, Greer IA, Petrie JR, Cobbe SM and Sattar N. Effects of 572 metformin on microvascular function and exercise tolerance in women with angina and 573 normal coronary arteries: a randomized, double-blind, placebo-controlled study. *J Am Coll* 

574 Cardiol. 2006;48:956-63.

Kao J, Tobis J, McClelland RL, Heaton MR, Davis BR, Holmes DR, Jr., Currier JW,
Investigators in the Prevention of Restenosis With T and Its Outcomes T. Relation of
metformin treatment to clinical events in diabetic patients undergoing percutaneous
intervention. *Am J Cardiol.* 2004;93:1347-50, A5.

15. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S
and Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in
patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *Lancet*.
2009;373:1765-72.

Levelt E, Piechnik SK, Liu A, Wijesurendra RS, Mahmod M, Ariga R, Francis JM,
Greiser A, Clarke K, Neubauer S, Ferreira VM and Karamitsos TD. Adenosine stress CMR
T1-mapping detects early microvascular dysfunction in patients with type 2 diabetes mellitus
without obstructive coronary artery disease. *J Cardiovasc Magn Reson*. 2017;19:81.

Larghat AM, Swoboda PP, Biglands JD, Kearney MT, Greenwood JP and Plein S.
The microvascular effects of insulin resistance and diabetes on cardiac structure, function, and perfusion: a cardiovascular magnetic resonance study. *Eur Heart J Cardiovasc Imaging*.
2014;15:1368-76.

591 18. Kramer CM, Barkhausen J, Bucciarelli-Ducci C, Flamm SD, Kim RJ and Nagel E.
592 Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. J
593 *Cardiovasc Magn Reson*. 2020;22:17.

Kellman P, Hansen MS, Nielles-Vallespin S, Nickander J, Themudo R, Ugander M
and Xue H. Myocardial perfusion cardiovascular magnetic resonance: optimized dual
sequence and reconstruction for quantification. *J Cardiovasc Magn Reson*. 2017;19:43.

597 20. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. *Obes Res.* 2003;11:1278-89.

599 21. Kirpichnikov D, McFarlane SI and Sowers JR. Metformin: an update. *Ann Intern* 600 *Med*. 2002;137:25-33.

Alexanderson-Rosas E, de Jesus Martinez A, Ochoa-Lopez JM, Calleja-Torres R,
Sierra-Fernandez C, Inarra-Talboy F, Meave-Gonzalez A, Alexanderson-Rosas G and
Gonzalez-Canudas J. [Effects of the combined treatment with Metformin/Glimepiride on
endothelial function of patients with type 2 diabetes mellitus. A positron emission
tomography (PET) evaluation study]. *Arch Cardiol Mex.* 2009;79:249-56.

406 23. van Haare J, Kooi ME, van Teeffelen JW, Vink H, Slenter J, Cobelens H, Strijkers
607 GJ, Koehn D, Post MJ and van Bilsen M. Metformin and sulodexide restore cardiac
608 microvascular perfusion capacity in diet-induced obese rats. *Cardiovasc Diabetol*.
609 2017;16:47.

A. Rahman H, Scannell CM, Demir OM, Ryan M, McConkey H, Ellis H, Masci PG,
Perera D and Chiribiri A. High-Resolution Cardiac Magnetic Resonance Imaging Techniques
for the Identification of Coronary Microvascular Dysfunction. *JACC Cardiovasc Imaging*.

613 2021;14:978-986.

614 25. Han Y, Xie H, Liu Y, Gao P, Yang X and Shen Z. Effect of metformin on all-cause 615 and cardiovascular mortality in patients with coronary artery diseases: a systematic review 616 and an updated meta-analysis. *Cardiovasc Diabetol*. 2019;18:96.

617 26. Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A and 618 Szabo E. Metformin and cancer risk and mortality: a systematic review and meta-analysis 619 taking into account biases and confounders. *Cancer Prev Res (Phila)*. 2014;7:867-85.

620 27. Morales DR and Morris AD. Metformin in cancer treatment and prevention. *Annu Rev*621 *Med*. 2015;66:17-29.

Bhat A, Sebastiani G and Bhat M. Systematic review: Preventive and therapeutic
applications of metformin in liver disease. *World J Hepatol*. 2015;7:1652-9.

29. Breining P, Jensen JB, Sundelin EI, Gormsen LC, Jakobsen S, Busk M, Rolighed L, Bross P, Fernandez-Guerra P, Markussen LK, Rasmussen NE, Hansen JB, Pedersen SB, Richelsen B and Jessen N. Metformin targets brown adipose tissue in vivo and reduces oxygen consumption in vitro. Diabetes Obes Metab. 2018;20:2264-2273. 30. Patrone C, Eriksson O and Lindholm D. Diabetes drugs and neurological disorders: new views and therapeutic possibilities. Lancet Diabetes Endocrinol. 2014;2:256-62. Neven E, Vervaet B, Brand K, Gottwald-Hostalek U, Opdebeeck B, De Mare A, 31. Verhulst A, Lalau JD, Kamel S, De Broe ME and D'Haese PC. Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder. Kidney Int. 2018;94:102-113. Chen Q, Thompson J, Hu Y and Lesnefsky EJ. Chronic metformin treatment 32. decreases cardiac injury during ischemia-reperfusion by attenuating endoplasmic reticulum stress with improved mitochondrial function. Aging (Albany NY). 2021;13:7828-7845. 33. Dziubak A, Wojcicka G, Wojtak A and Beltowski J. Metabolic Effects of Metformin in the Failing Heart. Int J Mol Sci. 2018;19. 34. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, Ramachandran A, Anaya-Cisneros M, Tian R and Lefer DJ. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res. 2009;104:403-11. 

674	
675	

Demographics	Metformin (n= 388)	No metformin (n=184)	P value
Age (years)	64 ±10	66 ±11	0.057
Male sex	252 (65)	125 (68)	0.482
White	222 (57)	122 (66)	0.038*
Asian	125 (32)	40 (22)	0.010*
Black	20 (5)	10 (5)	0.888
Other	20 (5)	12 (7)	0.506
<b>BSA</b> (m <sup>2</sup> )	1.98±0.2	1.97±0.3	0.942
Previous PCI/CABG/MI	107 (28)	35 (19)	0.027*
Current Smoker	83 (22)	46 (25)	< 0.001*
HTN	222 (58)	106 (58)	0.926
High cholesterol	241 (62)	98 (54)	0.044*
Previous stroke/TIA	16 (4)	18 (10)	0.008*
AF	39 (10)	39 (21)	< 0.001*
PVD	37 (10)	7 (4)	0.016*
HbA1C (mmol/mol)	60±16	56±15	0.022*
Cholesterol (mmol/l)	4.4±1.4	4.8±1.4	0.074

676

677 Table 1: Patient demographics by metformin status. P value is considered significant at the <0.05

678 and indicated by\*. Continuous variables are presented as mean  $\pm$  SD. Dichotomous variables are

679 presented as number (%). BSA: Body Surface Area, PCI: Percutaneous Coronary Intervention,

680 CABG: Coronary Artery Bypass Graft surgery, MI: Myocardial Infarction, HTN: Hypertension, TI:

681 Transient Ischaemic Attack, AF: Atrial Fibrillation, PVD: Peripheral Vascular Disease.

683

Medication	Metformin (n=388)	No Metformin (n=184)	P value
Aspirin/ other antiplatelet	254 (65)	89 (48)	<0.001*
DOAC/ Warfarin	41 (11)	34 (18)	0.012*
Statin	332 (86)	122 (66)	<0.001*
Beta blocker	209 (54)	114 (62)	0.086
ACE/ARB/Entresto	266 (69)	134 (72)	0.478
MRA	29 (8)	35 (19)	<0.001*
Diuretics	87 (22)	68 (37)	<0.001*
ССВ	116 (30)	40 (22)	0.034*
Nitrates	54 (14)	21 (11)	0.382
Insulin	53 (14)	33 (18)	0.199
Gliclazide	94 (23)	17 (9)	<0.001*
SGLT-2	44 (11)	9 (5)	0.037*
GLP-1	61 (16)	15 (8)	0.011*
Gliptin	25 (6)	5 (3)	0.059

684

685 Table 2: Patient medication divided by metformin status. P value is considered significant at the

686 <0.05 level and indicated by\*. Dichotomous variables are presented as number (%). DOAC: Direct

687 Oral AntiCoagulant; ACE: Angiotensin Converting Enzyme Inhibitor; ARB: Angiotensin Receptor

688 Blocker; MRA: Mineralocorticoid Receptor Antagonist; CCB: Calcium Channel Blocker; SGLT-2:

689 Sodium Glucose Cotransporter-2 inhibitor; GLP-1: Glucago-Like Peptide 1 agonist.

691

692

693

CMR Parameter	Metformin (n= 388)	No metformin (n=184)	P value
LVEF (%)	59±14	53 ±18	<0.001*
LVEDV (ml)	149±50	174±71	<0.001*
LV mass (g)	117±34	127± 39	0.002*
Global Stress MBF (ml/g/min)	1.74±0.6	1.62±0.5	0.019*
Adjusted global stress MBF** (ml/g/min)	1.74±0.03	1.67±0.04	<0.0001*
MPR	2.29±0.9	1.96±0.9	<0.001*
Adjusted MPR**	2.27±0.04	2.03±0.07	<0.0001*
LGE ischaemic	115 (30)	49 (27)	0.502
LGE non-ischaemic	89 (23)	50 (27)	0.502
No LGE	183 (47)	84 (46)	0.502
1.5T scanner	127 (33)	42 (23)	0.015*
3T scanner	261 (67)	142 (77)	0.015*

694 695

696 Table 3: CMR parameters based on metformin status. P value is considered significant at the <0.05697 level and indicated by\*. Continuous variables are presented as mean  $\pm$  SD. Dichotomous variables 698 are presented as number (%). \*\*Adjusted for age, sex, LVEF, LV mass, LVEDV, hypertension, 699 evidence of previous PCI, CABG, MI, BSA, ethnicity, CCB, nitrates, SGLT-2 inhibitors, GLP-1 700 agonists and gliclazide. MBF: Myocardial Blood Flow; MPR: MyocardialPperfusion Reserve; LV: 701 Left Ventricle; LVEF: Left Ventricular Ejection Fraction; LVEDV: Left Ventricular End-Diastolic 702 Volume; LGE: Late Gadolinium Enhancement, PCI: Percutaneous Coronary Intervention, CABG: 703 Coronary Artery Bypass Graft surgery, MI: Myocardial Infarction, BSA: Body Surface Area, CCB:

705 *peptide agonist.* 

<sup>704</sup> Calcium Channel Blocker; SGLT-2: Sodium glucose co-transporter 2 inhibitor; GLP-1-Glucagon like

#### 

Event	Metformin (n=388)	No Metformin (n=184)	P value	All patients (n=572)
MACCE**	53 (13.7)	29 (15.8)	0.503	82 (14)
Death	9 (2.3)	16 (8.7)	<0.001*	25 (4)
MI	12 (3.1)	3 (1.6)	0.307	15 (2.6)
Stroke	8 (2.1)	10 (5.4)	0.031*	18 (3.1)
Heart Failure hospitalisation	12 (3.1)	8 (4.3)	0.445	20 (3.5)
Coronary revascularisation	29 (7.5)	14 (7.6)	0.955	43 (7.5)

713 Table 4: MACCE events by metformin status. P value is considered significant at the <0.05 level and

714 indicated by\*. Data represented as number of events with percentage in brackets.\*\* First MACCE.

#### 

	Death	MACCE
Unadjusted		
Hazard ratio (Metformin)	0.22 [0.10-0.52], P<0.001*	0.87 [0.55-1.37], P=0.55
Adjusted		
Hazard ratio (Metformin)	0.29 [0.12-0.73], P=0.009*	0.92 [0.56-1.50], P=0.73

Table 5: Cox proportional hazard models. Death model was adjusted for age and LVEF. MACCE

model was adjusted for age, sex, LVEF, LVEDV, LV mass, stress MBF, MPR, hypertension. Square

brackets represent 95% confidence intervals. P value considered significant at <0.05 level and

indicated by\*.

LVEF: Left Ventricular Ejection Fraction; LVEDV: Left Ventricular End Diastolic Volume; MBF:

Myocardial Blood Flow; MPR: Myocardial Perfusion Reserve; MACCE: Major Adverse

Cardiovascular and Cerebrovascular Event; HTN: Hypertension.

750 751 752	Figure legends
753	Central illustration: Metformin in patients with Type 2 Diabetes Mellitus (T2DM) associates
754	with increased myocardial perfusion reserve (MPR) and is independently associated with
755	increased overall survival. MBF: Myocardial Blood Flow; HR: Hazard Ratio; CI: 95%
756	Confidence Intervals
757 758 759	
760	Figure 1: Kaplan-Meier hazard curves for all-cause mortality by metformin status. P value
761	is considered significant at $<0.05$ . Hazard curves are represented as blue line for no
762	metformin and green line for metformin.
763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780	
781	
782	
783 784	
785	
786	
787	
788	
789 700	
790 791	
702	
192 793	
794	



819 green line for metformin.

820